Figure 1.
TLS risk mitigation after 2 preinduction cycles with obinutuzumab. (A) ALC at baseline and at end of preinduction per patient. (B) Largest diameter of lymph node in millimeters, as assessed by CT scan at baseline and at end of preinduction per patient. (C) Per patient change in TLS risk category; 3 = high (ALC ≥25 × 109/L and largest diameter of all measurable lymph nodes ≥5 cm and <10 cm or largest diameter of all measurable lymph nodes ≥10 cm, regardless of the ALC), 2 = intermediate (ALC ≥25 × 109/L, or largest diameter of all measurable lymph nodes ≥ 5 cm and <10 cm), 1 = low (low: absolute lymphocyte count (ALC <25 × 109/L and largest diameter of all measurable lymph nodes <5 cm).3